SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogelon Mars

Dogelon Mars is generating significant community debate, with investors sharply divided between long-term holders awaiting a potential breakout and skeptics dismissing it as a stagnant project. While proponents highlight its history as an original meme coin and look for catalysts like token burns or ecosystem expansion, others are frustrated by prolonged price stagnation and the perception that it lags behind broader market movements.

Robot Money

Robot Money is generating polarized community interest, with proponents framing it as a high-growth AI-integrated play while skeptics label it as a potential pump-and-dump scheme.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is drawing significant investor interest as it approaches major clinical milestones, including pending Japanese regulatory approvals and upcoming trial readouts that the community views as key value drivers. Investors are actively discussing the company's strong cash position and the unique potential of its Alpha DaRT technology, leading to widespread bullish sentiment and recent analyst price target increases.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is seeing intense interest as investors weigh the impact of its upcoming first-ever halving against broader decentralized AI infrastructure developments and institutional institutional moves like Grayscale's recent ETF filing. Community sentiment is deeply polarized, with bulls focused on the token's scarcity model and subnet growth, while others express caution regarding the asset's current volatility and heavy dependence on market-wide trends.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as investors highlight its role as a critical infrastructure provider for real-world assets (RWAs) and institutional-grade data feeds. Community members are particularly focused on the project's token buyback program and its growing adoption by major financial institutions and government entities, contrasting its fundamental utility with the volatility of the broader meme coin market.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is surging as the market reacts to compelling Phase 1 clinical data for its lead oncology asset, TERN-701, which has triggered a flurry of analyst upgrades and heightened institutional interest. While investors are debating the long-term valuation and potential for a buyout, community sentiment remains sharply divided between those riding the massive momentum and skeptics wary of the stock's rapid appreciation based on early-stage trials.

VeChain, founded in 2015, is a sustainability-focused blockchain driving mass adoption of Web3. Its energy-efficient VeChainThor chain delivers fast, low-cost transactions, making blockchain accessible to millions worldwide. With partnerships including UFC, BCG, and Walmart, and over 2 million active users on VeBetter-powered apps, VeChain is proving real-world impact at scale.  In 2024, the VeChain Renaissance upgrade was launched, introducing Ethereum compatibility, dPoS consensus, and dynamic gas fees. It cut VTHO inflation and introduced StarGate NFT staking, where users lock VET to mint transferable NFTs that earn VTHO, can be delegated to validators, and serve as governance instruments. The upgrade also added new eco node tiers, lowering entry barriers while keeping rewards across higher staking levels.  By combining adoption, upgraded tokenomics, and inclusive staking, VeChain is positioning itself as a leading blockchain where usage, growth, and rewards fuel long-term value creation.

Vechain

VeChain is currently a focal point of intense community polarization, with long-term holders expressing extreme frustration over stagnant price action and the foundation's treasury management, while others double down on accumulation in anticipation of future utility and upcoming network upgrades. Discussion remains dominated by debates over leadership transparency, the impact of high-profile partnerships, and skepticism regarding whether the asset will ever recapture its previous highs.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco Systems is trending as investors weigh its pivot toward AI-driven networking infrastructure and recurring software revenue against concerns about long-term valuation comparisons to the dot-com era. The community is actively debating the stock's potential to break past historic resistance levels, with many focusing on whether recent hyperscale order growth and strategic partnerships can sustain its momentum or if margin pressures will cap the rally.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is capturing significant attention as investors speculate on a long-awaited breakout, with the community actively debating the asset's potential as a store of value and comparing its historical consolidation to newer crypto projects. The conversation is driven by intense interest in upcoming regulatory clarity and the asset's technical readiness, while many market participants are bracing for volatility following recent price resistance.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

ProShares UltraShort Bloomberg Natural Gas is trending as investors actively debate the impact of the May contract rollover, shifting weather forecasts, and the persistence of short-term volatility. The community is focused on the tension between potential inventory draws and a broader fundamental outlook that leans toward supply-side pressure, with many participants actively trading the divergent sentiment between those betting on tactical bounces and those maintaining long-term bearish positioning on natural gas.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Implied Volatility Surging for Kura Oncology Stock Options

Investors need to pay close attention to Kura Oncology stock based on the movements in the options market lately.

FY2027 EPS Forecast for Kura Oncology Lowered by Analyst

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Stock analysts at Brookline Capital Acquisition dropped their FY2027 earnings estimates for Kura Oncology in a note issued to investors on Thursday...

Kura Oncology (NASDAQ:KURA) Given New $36.00 Price Target at Wedbush

Wedbush reduced their price target on Kura Oncology from $38.00 to $36.00 and set an "outperform" rating for the company in a research report on Friday...

Kura Oncology Q4 Earnings Call Highlights

Kura Oncology (NASDAQ:KURA) executives used the company's fourth-quarter and fiscal 2025 earnings call to highlight what CEO Troy Wilson called a defining year, driven by the FDA approval of Komzifti...

Kura Oncology (NASDAQ:KURA) Shares Gap Down After Earnings Miss

Kura Oncology (NASDAQ:KURA) Shares Gap Down Following Weak Earnings...

Kura Oncology (NASDAQ:KURA) Releases Earnings Results, Misses Estimates By $0.50 EPS

Kura Oncology (NASDAQ:KURA - Get Free Report) released its earnings results on Thursday. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.50...

Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates

Kura Oncology (KURA) delivered earnings and revenue surprises of -28.67% and -41.85%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Kura Oncology Q4 Earnings Summary & Key Takeaways

Wall Street Zen Downgrades Kura Oncology (NASDAQ:KURA) to Sell

Wall Street Zen cut Kura Oncology from a "hold" rating to a "sell" rating in a report on Monday...

Kura Oncology (NASDAQ:KURA) Upgraded at Zacks Research

Zacks Research raised Kura Oncology from a "strong sell" rating to a "hold" rating in a research report on Thursday...

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Current Price	$8.65
Prev Close	$8.84
Open	$8.91
Dividend Yield	0.00%
50-Day Moving Average	$8.70
Beta	1.02
Avg. Volume	1.46M
PE Ratio	-2.72

52-Week High	$12.49
52-Week Low	$5.41
Market Capitalization	$764.05M
EPS (Annual)	-$3.18
Price to Book	4.36
Revenue Per Employee	$259,546.15

KURA
Kura Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KURA News

KURAKura Oncology Inc